NEW YORK, July 14, 2016 /PRNewswire/ --
On Wednesday, July 13, 2016, the NASDAQ Composite ended the trading session at 5,005.73, down 0.34%; the Dow Jones Industrial Average edged 0.13% higher, to finish at 18,372.12; and the S&P 500 closed at 2,152.43, up 0.01%. Stock-Callers.com has initiated coverage on the following equities: Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), CytRx Corporation (NASDAQ: CYTR), and Progenics Pharmaceuticals Inc. (NASDAQ: PGNX). Learn more about these stocks by accessing their free notes at:
On Wednesday, shares in Cambridge, Massachusetts headquartered biopharmaceutical company, Merrimack Pharmaceuticals Inc., ended the session 5.80% lower at $5.36 with a total volume of 1.99 million shares traded. The Company offers ONIVYDE that is used for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The stock is trading 15.00% below its 50-day moving average. Moreover, shares of Merrimack Pharmaceuticals have a Relative Strength Index (RSI) of 39.14. Sign up and read the free notes on MACK at:
Alnylam Pharmaceuticals Inc.'s stock finished Wednesday's session 1.84% lower at $62.82 with a total volume of 983,419 shares traded. The Company's shares have advanced 3.58% in the past one month. The stock is trading above its 50-day moving average by 4.10%. Alnylam Pharmaceuticals' stock has an RSI of 58.53. The complimentary notes on ALNY can be accessed at:
Los Angeles, California headquartered biopharmaceutical research and development company, CytRx Corp.'s stock lost 2.96% to close the day at $0.98. The stock recorded a trading volume of 7.84 million shares, which was above its three months average volume of 1.48 million shares. The stock is trading 61.04% below its 50-day moving average. Additionally, CytRx's stock has an RSI of 23.34. Register for free on Stock-Callers.com and access the latest notes on CYTR at:
On Wednesday, shares in Progenics Pharmaceuticals Inc. which develops medicines for oncology in the U.S. and internationally, recorded a trading volume of 1.15 million shares, which was higher than their three months average volume of 885,930 shares. The stock ended the day 5.02% lower at $4.92. The Company's shares have advanced 7.66% in the last one month and 1.65% in the previous three months. The stock is trading above its 50-day moving average by 2.10%. Furthermore, shares of Progenics Pharmaceuticals have an RSI of 53.00. Get free access to your notes on PGNX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA